TrialJAMA network open2024

A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial.

What the trial testedas reported · 509 people · 2024

Not counted

−0.30percentage points−0.40 to −0.10

As reported

difference −0.3 %, 95% CI −0.40 to −0.10

Not counted

−0.40percentage points−0.60 to −0.20

As reported

difference −0.4 %, 95% CI −0.60 to −0.20

the abstract, start to end

… [SE, 0.2%]; adjusted LSM difference, -0.3% [95% CI, -0.4% to -0.1%]) and empagliflozin …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.3−0.40 to −0.10

Glycemic control

−0.4−0.60 to −0.20

MetforminSGLT2 inhibitorsGlycemic control

1 / 3

2024

2025

2026

this papertrialcites it